Skip to main content
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1999 Jul;6(4):447–451. doi: 10.1128/cdli.6.4.447-451.1999

Evaluation of Newly Developed Immunoperoxidase Monolayer Assays for Detection of Antibodies against Bovine Herpesvirus 4

G J Wellenberg 1,*, E M A van Rooij 1, J Maissan 1, J T Van Oirschot 1
PMCID: PMC95706  PMID: 10391841

Abstract

This study describes the evaluation of immunoperoxidase monolayer assays (IPMAs) for detection of antibodies against bovine herpesvirus 4 (BHV4) DN-599 or BHV4 LVR 140 in sera of cattle. We compared the quality of these IPMAs with the quality of a BHV4 indirect enzyme-linked immunosorbent assay (ELISA). In addition, a preliminary serological survey of BHV4 antibodies was carried out to estimate the seroprevalence of BHV4 in Dutch cattle at different ages. The specificities of both BHV4 IPMAs were 1.00. The geometrical mean titers (detection limit) of the BHV4 IPMAs were twice as high as that of the BHV4 indirect ELISA. In experimentally infected cattle, BHV4 antibodies were detectable by IPMAs 16 to 18 days postinfection, which was almost 2 weeks earlier than in the indirect ELISA. The reproducibility of the BHV4 DN-599 IPMA (κD value, 0.92) and of the BHV4 LVR 140 IPMA (κD value, 0.87) were good. For field sera the overall agreement between the BHV4 indirect ELISA and the two BHV4 IPMAs, DN-599 and LVR 140, was 95 and 96%, respectively. The serological-survey study showed that the estimated seroprevalence of BHV4 in Dutch cattle was 16 to 18% and that the percentage of BHV4-positive animals varied by age category (between 6 and 43%). In summary, the two BHV4 IPMA formats have several advantages that make IPMA a useful alternative to the BHV4 indirect ELISA for detecting BHV4 antibodies in cattle.


Bovine herpesvirus 4 (BHV4), a group of virus strains belonging to the Gammaherpesvirinae (17), is distributed worldwide, and BHV4 strains have been isolated from cattle with a variety of clinical symptoms (8, 12, 14, 20, 23, 24). For antibody detection, a sensitive test is required because the humoral immune response of cattle to BHV4 infections is characterized by a low neutralizing antibody response, or even by the absence of neutralizing antibodies (21). Other methods have been developed to detect BHV4 antibodies in serum, such as complement fixation (9), the indirect fluorescent-antibody test (IFAT) (18), and the indirect enzyme-linked immunosorbent assay (iELISA) (7). According to Guo et al. (9), the complement fixation test was less sensitive than the iELISA for the detection of immunoglobulin G (IgG) to BHV4. The IFAT and the iELISA are the most common tests to be used for detection of BHV4 antibodies, but the IFAT is laborious, particularly if quantitative results are required (7). Also, cross-reactions between BHV4 and other herpesviruses have been recorded by IFAT (11, 16). Edwards and Newman (7) reported that the iELISA appeared to be as sensitive as the IFAT, but these results were based only on sera collected from experimentally infected cattle. Until now, no thorough validation of any BHV4 ELISA has been published. Because there is a need for an easy test to detect BHV4 antibodies, we developed an immunoperoxidase monolayer assay (IPMA). IPMAs have proven to be an easy method and a valuable tool for the diagnosis of several infectious diseases (19); for instance, it is a common method for the detection of antibodies against porcine reproductive and respiratory syndrome virus in pigs (10).

The purpose of this study was to evaluate newly developed BHV4 IPMAs which are based on the American BHV4 reference strain, DN-599 (13), and on LVR 140, the Belgian BHV4 reference strain (26), which belongs to the European Movar 33/63-like group (22). The results of the IPMAs were compared with the results of a BHV4 iELISA. Data on the prevalence of BHV4 antibodies in Dutch cattle are also presented.

MATERIALS AND METHODS

BHV4 IPMA. (i) Preparation of BHV4 IPMA plates.

Trypsinized embryonic bovine trachea (EBTr) cells were resuspended in Earle’s minimal essential medium cell culture medium containing 10% horse serum and 0.5% antibiotic mix (antibiotic stock solution containing 107 IU of penicillin G, 8.6 × 106 IU of streptomycin, 1% kanamycin, and 5 × 106 IU of nystatin per 1 liter of aquadest) and seeded into wells of a 96-well cell culture plate (Greiner). Each well contained 100 μl of an EBTr cell suspension of approximately 7.5 × 104 cells/ml. The plates were placed in a humidified incubator at 37°C with 5% CO2. After 3 to 4 days, when the monolayer was 100% confluent, the cell culture medium was discarded and the cells were infected with 25 μl (containing 102 50% tissue culture infective doses/ml) of the BHV4 DN-599 strain (ATCC VR631) or the BHV4 LVR 140 strain (kindly provided by E. Thiry). After 1 h at 37°C (5% CO2), a volume of 75 μl of EMEM (containing 2% horse serum and 0.5% antibiotic mix) was added to each well. When a cytopathogenic effect started to appear, the incubation was stopped. The virus-cell culture medium was discarded, and a volume of 150 μl of 4% formaldehyde in phosphate-buffered saline (PBS) was added to the wells for 10 min at 18 to 25°C. The fluid was poured off, and again a volume of 150 μl of 4% formaldehyde in PBS (fixative) was added to the wells. The plates were sealed and stored at 4°C.

(ii) Performance of BHV4 IPMA.

Prior to use, the fixative was removed and the plates were washed once with 100 μl/well of a 2% Triton X-100 solution (Sigma) in PBS. To reduce nonspecific reactions, the plates were first incubated with a volume of 100 μl of 2% Triton X-100 in PBS for 60 min at 37°C. After the Triton X-100 solution was discarded, the plates were incubated with 75 μl of PBS (containing 10% horse serum)/well for 60 min at 37°C. Serum test samples were diluted 1:20 in IPMA buffer (38.5 g of NaCl, 2% Tween 80, 0.1% NaN3, and 10% horse serum per 1 liter of PBS). After the preincubation, the PBS-horse serum solution was discarded and a volume of 75 μl of the 1:20 prediluted serum sample was added to the wells and incubated at 37°C for 1 h. The plates were washed six times in wash solution (PBS containing 1% Tween 80 [Merck]). A volume of 75 μl of the conjugate solution was added to the wells (1:200 dilution of horseradish peroxidase labeled rabbit anti-bovine immunoglobulin [Dakopatt] in IPMA buffer [without NaN3]) and incubated at 37°C for 1 h. The plates were washed five times as described above, and 75 μl of substrate-chromogen (H2O2/3-amino-9-ethylcarbazole) was added and incubated at 18 to 25°C for 30 min. Without stopping the reaction, the results were read under a light microscope by at least two persons, independently of each other. The serum samples were retested if the interpretations of the two persons were not the same. Positive reactions were characterized by an intense red-brown staining mainly of the nuclei of the EBTr cells, indicating binding of antibodies to BHV4 DN-599 or BHV4 LVR 140 antigens (Fig. 1). The results were interpreted as either negative (a titer of <20) or positive (a titer of ≥20).

FIG. 1.

FIG. 1

(A) BHV4 IPMA-positive staining reactions, which are characterized by red-brown staining mainly of the nuclei of BHV4-infected EBTr cells, indicate the binding of serum antibodies to BHV4 antigens. (B) Negative reactions are characterized by the absence of color.

BHV4 iELISA.

The BHV4 iELISA (BIO-X, Brussels, Belgium) was performed as described by the manufacturer; it follows the principle of an iELISA. Briefly, the odd wells (antigen wells) of the ELISA microplate are coated with a BHV4 LVR 140-cell suspension lysate, while the even wells (control wells) are coated with a lysate of cell suspension. Volumes of 100 μl (each) of 1:100-diluted serum samples, including the positive reference serum sample of the kit, were added to the antigen and the control wells and incubated at 18 to 25°C for 1 h. The plates were washed six times, and a volume of 100 μl of conjugate (horseradish peroxidase-labeled anti-bovine IgG1 monoclonal antibody) was added to each well. The plates were incubated at 18 to 25°C for 1 h and washed again (six times). After the washing, a volume of 100 μl of the substrate-chromogen (H2O2-tetramethylbenzidine) was added to each well. After 10 min the color reaction was stopped by the addition of 50 μl of 1 M phosphoric acid. The optical density (OD) value was determined by an ELISA plate reader at 450 nm. The interpretation of the results was done as follows: the OD value of the control well was subtracted from the OD value of the antigen well. The net OD value was compared with the net OD value of the positive reference serum sample by dividing the net OD value of the serum sample by the net OD value of the positive reference serum sample. Finally, this value was multiplied with the coefficient of the iELISA batch, as noted for each BHV4 iELISA batch. Serum samples with values of <0.2 were classified as negative, and serum samples with values of ≥0.2 were classified as positive for BHV4 antibodies.

Controls.

To guarantee the quality of the tests, control serum samples were incorporated into ELISA test plates and into each IPMA test run. Therefore a strong positive, a dilution of a positive (weak-positive), and a negative serum sample were used (15). The BHV4-positive serum samples were kindly provided by E. Thiry and by G. Czaplicki (Belgium), while the negative control was provided by E. Van Opdenbosch (Belgium). The results of test runs were accepted if the controls were correct.

Specificity.

The specificities of the BHV4 tests were determined by testing monospecific serum samples containing high antibody levels directed against BHV1 (number of serum samples [n] = 5), BHV2 (n = 1), bovine respiratory syncytial virus (n = 3), parainfluenza virus type 3 (n = 3), bovine leukemia virus (n = 2), bovine immunodeficiency virus (n = 2), bovine viral diarrhea virus (n = 3) rotavirus (n = 4), and coronavirus (n = 4). The specificities of the BHV4 IPMAs and the BHV4 ELISA were also determined by testing 69 individual serum samples collected from 69 specified-pathogen-free (SPF) cattle (cattle born by caesarean section, held in isolation stables, and raised colostrum free).

Detection limit.

For the determination of the detection limits for both BHV4 IPMAs and the BHV4 iELISA, the following sera were used: the positive bovine BHV4 antiserum of the Central Veterinary Laboratory (Weybridge, England), one serum sample collected from one experimentally infected SPF calf (4797), and randomly chosen positive serum samples of cattle from the field study (n = 8). The sera were titrated in serial twofold dilutions, starting at a dilution of 1:20. The detection limit was defined as the reciprocal of the highest dilution giving a positive reaction.

Experimental infection.

Two SPF calves (4797 and 4798), 3 weeks of age, were intranasally inoculated with 10 ml of 106.5 50% tissue culture infective doses of BHV4 DN-599 (ATCC VR631; bovine viral diarrhea virus and Mycoplasma free)/ml. Pre- and postinoculation serum samples were collected and tested for BHV4 antibodies. The serum samples were tested in the BHV4 IPMAs and the BHV4 iELISA in a 1:20 dilution. Positive serum samples were titrated in serial twofold dilutions, starting at a dilution of 1:20.

Reproducibility.

The reproducibility of the BHV4 tests was calculated from the results of duplicate tests by use of the Kappa test (2). Kappa (κD) was defined as the quotient of the observed proportion of agreement beyond chance and the maximal proportion of agreement. Therefore, serum samples (n = 150) of six randomly chosen BHV4-positive herds of the field study were tested twice on two different occasions, at least 2 months apart, using new IPMA reagents and ELISA kits with different lot numbers.

Field sera.

Field sera were used to compare the newly developed BHV4 IPMAs with the iELISA and to estimate the BHV4 seroprevalence in Dutch cattle. For that purpose, a total of 750 serum samples were collected at random from 30 randomly chosen Dutch herds (25 serum samples per herd). These herds had participated in a field study for BHV1 marker vaccine efficacy (3). The date of birth of each animal was recorded to estimate the BHV4 seroprevalence in Dutch cattle at different ages.

Statistical analyses and data processing.

Statistical analysis was performed on the data in Table 1 by the Friedman nonparametric two-way analysis of variance test, followed by the Wilcoxon signed-rank test (one-sided test) for pairwise comparison of both IPMAs with the iELISA. The data were processed with Statistix for Windows, version 2.0.

TABLE 1.

Titer of antibody against BHV4 in sera of cattle as determined in BHV4 IPMAs and BHV4 iELISA (n = 10)

Serum BHV4 antibody titer
BHV4 DN-599 IPMA BHV4 LVR 140 IPMA BHV4 LVR 140 iELISA
CVLa serum 320 320 320
4797 24/5 320 320 40
Herd A
 Cow 1 640 640 320
 Cow 2 1,280 640 1,280
Herd B
 Cow 1 640 1,280 640
 Cow 2 640 1,280 160
Herd C
 Cow 1 640 640 160
 Cow 2 1,280 1,280 1,280
Herd D
 Cow 1 640 320 320
 Cow 2 640 1,280 640
Geometric mean 640 686 343
a

CVL, Central Veterinary Laboratory. 

RESULTS

Evaluation of the BHV4 IPMAs. (i) Specificity.

No positive reactions were observed in the BHV4 IPMAs and the BHV4 iELISA with the monospecific serum samples containing high antibody levels directed against BHV1, BHV2, bovine respiratory syncytial virus, parainfluenza virus type 3, bovine leukemia virus, bovine immunodeficiency virus, bovine viral diarrhea virus, rotavirus, and coronavirus. In addition, all 69 serum samples collected from the SPF cattle reacted negative in the three BHV4 tests, indicating test specificities of 100%.

(ii) Detection limit.

The geometrical mean titers (reciprocal of the mean logarithmic titers) of the BHV4 DN-599 IPMA, the BHV4 LVR 140 IPMA, and the BHV4 iELISA were 640, 686, and 343, respectively. Hence, the detection limits of both BHV4 IPMAs were twice as high as that of the BHV4 iELISA (Table 1). Statistical analyses by the Friedman test showed that the differences between BHV4 antibody titers in both BHV4 IPMAs and those in the BHV4 iELISA were statistically significant (P value, 0.048). The one-sided P value, calculated by the Wilcoxon signed-rank test, was 0.031 for BHV4 DN-599 IPMA–BHV4 iELISA and 0.023 for BHV4 LVR 140–BHV4 iELISA.

(iii) Experimentally infected cattle.

The BHV4 IPMAs first demonstrated a BHV4 antibody response around 16 to 18 days after experimental infection; the iELISA first demonstrated a response around 30 days after experimental infection (Table 2). In the commercial BHV4 iELISA, serum samples of experimentally infected cattle were screened for BHV4 antibodies in a 1:20 dilution instead of a 1:100 dilution. For the screening of serum samples for BHV4 antibodies, a 1:100 serum dilution has been recommended by the manufacturer. At this dilution, no BHV4 antibody responses were detectable at day 37 (calf 4797), or even at day 44 (calf 4798), postinfection.

TABLE 2.

Antibody responses against BHV4 in experimentally infected calves as determined in the BHV4 IPMAs and the BHV4 iELISA

Day postinfection BHV4 antibody titer
IPMA
iELISA
DN-599
LVR 140
4797 4798
4797a 4798 4797 4798
 0 <20 <20 <20 <20 <20 <20
 7 <20 <20 <20 <20 <20 <20
11 <20 <20 <20 <20 <20 <20
14 <20 <20 <20 <20 <20 <20
16 <20 <20 <20 20 <20 <20
18 20 40 20 40 <20 <20
21 80 80 80 80 <20 <20
23 160 80 320 160 <20 <20
30 320 160 320 320 40 20
37 640 320 320 320 80 20
44 640 320 320 320 160 40
a

Calf number. 

(iv) Reproducibility.

The reproducibilities of the BHV4 tests were good. The overall agreements of duplicate test results were as follows: BHV4 DN-599 IPMA, 0.96 [(83 + 62)/150]; BHV4 LVR 140, 0.94 [(75 + 66)/150]; and BHV4 iELISA, 0.97 [(87 + 59)/150]. Based on these results the κD values of the BHV4 tests were as follows: DN-599 IPMA, 0.92; BHV4 LVR 140 IPMA, 0.87; and BHV4 iELISA, 0.96.

(v) Field sera.

Of the 750 field serum samples, 120 (16.0%), in the BHV4 DN-599 IPMA and 135 (18.0%) in the BHV4 LVR 140 IPMA scored positive for BHV4 antibodies, while in the BHV4 iELISA, 134 (17.9%) of the 750 field serum samples scored positive (Table 3). For field sera, the overall agreements of the BHV4 DN-599 IPMA and the BHV4 LVR 140 IPMA with the BHV4 iELISA were 95 and 96%, respectively. The overall agreement between the BHV4 DN-599 IPMA and the BHV4 LVR 140 IPMA was 98% (n = 750).

TABLE 3.

Concurrence of BHV4 IPMA and BHV4 iELISA results for field sera (n = 750)

IPMA Resulta No. of samples
BHV4 iELISAb
BHV4 DN-599 IPMAc
+ +
BHV4 DN-599c + 107 13
27 603
BHV4 LVR 140c + 119 16 120 15
15 600 0 615
a

+, positive; −, negative. 

b

Titer of <100 was considered negative; titer of ≥100 was considered positive. 

c

Titer of <20 was considered negative; titer of ≥20 was considered positive. 

Serological survey: Dutch seroepidemiological field study.

Based on the results of the three BHV4 tests (Table 3), 16 to 18% of the 750 Dutch field sera tested reacted positive for BHV4 antibodies. In 17 of the 30 herds examined (57%), BHV4 antibodies were detected in the BHV4 IPMAs. The herd prevalence of BHV4 antibodies varied between 0 and 76%, and within positive herds the seroprevalence of BHV4 antibodies varied by age category (Fig. 2). Cattle 5 years old and older showed the highest BHV4 seroprevalence: 43% of the sera contained antibodies to BHV4. The lowest level of BHV4 antibodies (6 to 7%) was found in the group of 0.5- to 2-year-old cattle. In young calves (between 0 and 6 months old) the BHV4 seroprevalence was 31%. Figure 2 shows only the results of the BHV4 LVR 140 IPMA for BHV4 seroprevalence in Dutch cattle at different ages; the same patterns were observed with the BHV4 DN-599 IPMA and the BHV4 iELISA.

FIG. 2.

FIG. 2

BHV4 seroprevalence in Dutch cattle at different ages as assessed by the BHV4 LVR 140 IPMA.

DISCUSSION

Our study shows that the BHV4 DN-599 and BHV4 LVR 140 IPMAs can be used for the screening of herds for BHV4 antibodies as an alternative to the BHV4 iELISA. Based on the specificity, detection limit, results from early-infection sera collected from calves, and reproducibility, the newly developed BHV4 IPMAs are reliable practical tests for the detection of BHV4 antibodies. In this evaluation study, the BHV4 IPMA specificities (100%) are comparable with those of the BHV4 iELISA (100%). The data on the detection limits (analytical sensitivity) and the experimental infection sera (diagnostic sensitivity) for both BHV4 IPMAs are even better than those of the BHV4 iELISA. The geometrical mean antibody titers (detection limits) of the BHV4 IPMAs were twice as high as the geometrical mean antibody titer of the BHV4 iELISA, and the differences between the BHV4 antibody titers of both BHV4 IPMAs and those of the BHV4 iELISA were statistically significant (P value, <0.05). The BHV4 IPMAs were able to detect BHV4 antibody responses 16 to 18 days post-experimental infection. Even when sera were tested in the commercial BHV4 iELISA in a 1:20 dilution, instead of a 1:100 dilution, no BHV4 antibody response was detectable within 30 days postinfection. One of the explanations for the inefficient detection of BHV4 antibodies could be that the commercial BHV4 iELISA detects only bovine IgG1. The immunoglobulin-specific conjugate, used in the BHV4 IPMAs to detect antibodies in the bovine serum samples, is known to have affinity for all bovine immunoglobulin subclasses (IgM, IgG1, IgG2, etc.). The iELISA described by Edwards and Newman (7) was based on the detection of bovine IgG (IgG1 and IgG2) and detected BHV4-specific antibodies in experimentally infected calves 21 days after primary infection. The calves (infected with Movar 33/63) showed a response to the primary inoculation, which consisted mainly of IgG1. However, the detection of IgG2 and IgM could have been underestimated due to competitive inhibition by high levels of IgG1 (7). Although other parameters, e.g., buffer solutions and substrate, could also influence the difference in sensitivity of IPMA versus iELISA, the choice of the anti-bovine Ig conjugate is probably the most relevant factor. The reproducibilities of the BHV4 DN-599 IPMA (κD value, 0.92) and the BHV4 iELISA (κD value, 0.96) are good, while the reproducibility of the BHV4 LVR 140 is somewhat lower but still acceptable (κD value, 0.87).

The seroepidemiological field study shows that the estimated BHV4 seroprevalence in Dutch cattle is 16 to 18%. The BHV4 seroprevalences in cattle determined in countries surrounding the Netherlands are comparable with those in Dutch cattle. In the northern part of Belgium 15%, and in Wallony (Belgium) 29%, of the cattle older than 1 year were BHV4 seropositive (24). In the former West Germany, the BHV4 seroprevalence in cattle was 18.4%, while 38% of the bulls used for artificial insemination contained BHV4 antibodies (23). Young calves (<6 months old) had antibodies directed against BHV4. These antibodies are probably of maternal origin and not the result of a BHV4 infection. According to Van Opdenbosch et al. (25), 38% of veal calves in Belgium (<3 months old) had maternal antibodies against BHV4, and only 3% of the BHV4-negative veal calves seroconverted within a period of 3 months. In this study, an increase in BHV4-seropositive animals was recorded within the group of 2- to 3-year-old cattle. Hence, it is likely that most cattle become infected after introduction into the dairy herd. Whether there is a relation between this finding and that of Czaplicki and Thiry (4), who reported an association between BHV4 seropositivity and abortion in cows, is unknown.

Although the BHV4 group comprises a collection of antigenically closely related isolates (1), and no major antigenic differences between BHV4 isolates have been demonstrated by cross-serological analysis with polyvalent antisera (5), the evaluation of the newly developed BHV4 IPMA was based on two different BHV4 strains. The IPMAs were performed with the American BHV4 DN-599 reference strain and the Belgian LVR 140 reference strain, which belongs to the European Movar 33/63-like group (22), because the use of monoclonal antibodies showed some differences in the antigenic patterns of BHV4 isolates (6) and BHV4 strains can be isolated in many countries all over the world. Dubuisson et al. (6) confirmed the close antigenic relationships between BHV4 isolates by comparison of field isolates with BHV4 monoclonal antibodies, but some monoclonal antibodies recognized all BHV4 isolates while others allowed differentiation among them. Our data support the finding that there could be some minor differences in the antigenic patterns of BHV4 isolates, because the results, obtained with field sera, showed some slight differences between the BHV4 DN-599 IPMA and the BHV4 LVR 140 IPMA. Fifteen field serum samples reacted positive in the BHV4 LVR 140 IPMA, while these sera did not react in the BHV4 DN-599 IPMA. Thirteen of the 15 sera also reacted positive in the BHV4 iELISA, in which the plates were coated with a BHV4 LVR 140-cell suspension lysate. Differences in affinities of certain immunoglobulins of cattle for the different BHV4 strains could be an explanation, but another explanation could be the differences in antigenic expression or differences in the exposure of certain BHV4 antigens. Probably the antigenic expression and antigen exposure of Dutch BHV4 strains are more related to those of BHV4 LVR 140 than to those of BHV4 DN-599.

The BHV4 IPMA has several advantages compared to the BHV4 iELISA, e.g., this study shows better analytical sensitivity results and the IPMA can be more easily adapted to the BHV4 strain of choice (for example, the BHV4 strain which has been isolated in the area of interest) while the commercial BHV4 iELISA is based on the use of BHV4 LVR 140. This study also shows that, in comparison to the BHV4 iELISA, the BHV4 IPMA, which is based on the detection of all bovine immunoglobulin subclasses, is the test of choice for the early detection of BHV4 antibodies in bovine serum samples. A disadvantage of the IPMA is that it depends on subjective readings of test results whereas the iELISA is more objective because of the use of automatic readers. IPMA test results need to be interpreted by at least two trained persons to reduce the subjectivity of readings of test results (as indicated in Materials and Methods).

In conclusion, the BHV4 IPMA is a reliable practical test for the screening of cattle for BHV4 antibodies, and it is a useful alternative to iELISA for detecting BHV4 antibodies in cattle.

ACKNOWLEDGMENTS

We gratefully acknowledge J. de Bree for statistical advice, E. Thiry for providing the BHV4 LVR 140 strain, and G. Czaplicki and E. Van Opdenbosch for providing BHV4 sera.

REFERENCES

  • 1.Bartha A, Fadol A M, Liebermann H, Ludwig H, Mohanty S B, Osorio F A, Reed D E, Storz J, Straub O C, Van der Maaten M J, Wellemans G. Problems concerning the taxonomy of the ‘Movar-Type’ bovine herpesviruses. Intervirology. 1987;28:1–7. doi: 10.1159/000149991. [DOI] [PubMed] [Google Scholar]
  • 2.Bloch D A, Kreamer H C. 2 × 2 kappa coefficients: measures of agreement or association. Biometrics. 1989;45:269–287. [PubMed] [Google Scholar]
  • 3.Bosch J C, De Jong M C M, Franken P, Krankena K, Hage J J, Kaashoek M J, Maris-Veldhuis M A, Noordhuizen J P T M, Van der Poel W H M, Verhoef J, Weerdmeester K, Zimmer G M, Van Oirschot J T. An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field. Vaccine. 1998;16:265–271. doi: 10.1016/s0264-410x(97)00166-7. [DOI] [PubMed] [Google Scholar]
  • 4.Czaplicki G, Thiry E. An association exists between bovine herpesvirus-4 seropositivity and abortion in cows. Prev Vet Med. 1998;33:235–240. doi: 10.1016/s0167-5877(97)00036-6. [DOI] [PubMed] [Google Scholar]
  • 5.Dubuisson J, Thiry E, Thalasso F, Bublot M, Pastoret P-P. Biological and biochemical comparison of bovid herpesvirus-4 strains. Vet Microbiol. 1988;16:339–349. doi: 10.1016/0378-1135(88)90015-6. [DOI] [PubMed] [Google Scholar]
  • 6.Dubuisson J, Thiry E, Bublot M, Sneyers M, Boulanger M, Guillaumme D, Pastoret P-P. Production and characterization of monoclonal antibodies to bovid herpesvirus-4. Vet Microbiol. 1989;19:305–315. doi: 10.1016/0378-1135(89)90096-5. [DOI] [PubMed] [Google Scholar]
  • 7.Edwards S, Newman R H. Detection of antibodies to bovid herpesvirus 4 by ELISA. Vet Microbiol. 1985;10:149–154. doi: 10.1016/0378-1135(85)90016-1. [DOI] [PubMed] [Google Scholar]
  • 8.Giangaspero M, Vacirca G, Van Opdenbosch E, Blondeel H. Epidemiological survey on virus diseases of cattle in North West Syria. Tropicultura. 1992;10:55–57. [Google Scholar]
  • 9.Guo W Z, Shen D T, Evermann J F, Gorham J R. Comparison of an enzyme-linked immunosorbent assay and a complement-fixation test for the detection of IgG to bovine herpesvirus type 4 (bovine cytomegalovirus) Am J Vet Res. 1988;49:667–670. [PubMed] [Google Scholar]
  • 10.Houben S, Callebaut P, Pensaert M B. Comparative study of a blocking enzyme-linked immunosorbent assay and the immunoperoxidase monolayer assay for the detection of antibodies to the porcine reproductive and respiratory syndrome virus in pigs. J Virol Methods. 1995;51:125–128. doi: 10.1016/0166-0934(94)00135-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ludwig H. Bovine herpesviruses. In: Roizman B, editor. The herpesviruses. New York, N.Y: Plenum Press; 1983. pp. 135–214. [Google Scholar]
  • 12.Metzler A E, Wyler R. Praevalenz des Bovinen Herpesvirus 4 in der Schweizerischen Rinderpopulation und mögliche serologische Kreuzreaktion mit dem Bovinen Herpesvirus 1 (IBR/IPV-Virus) Schweiz Arch Tierheilkd. 1986;128:459–467. [PubMed] [Google Scholar]
  • 13.Mohanty S B, Hammond R C, Lillie M G. A new bovine herpesvirus and its effect on experimentally infected calves. Arch Gesamte Virusforsch. 1971;33:394–395. doi: 10.1007/BF01254696. [DOI] [PubMed] [Google Scholar]
  • 14.Naeem K, Goyal S M, Werdin R E. Prevalence of bovid herpesvirus-4 and its antibody in cattle in Minnesota. Am J Vet Res. 1989;50:1931–1935. [PubMed] [Google Scholar]
  • 15.Office International des Epizooties. Manual of standards for diagnostic tests and vaccines. 3rd ed. Paris, France: Office International des Epizooties; 1996. [Google Scholar]
  • 16.Osorio F A, Reed D E, Van der Maaten M J, Metz C A. Comparison of the herpesviruses in cattle by DNA restriction endonuclease analysis and serologic analysis. Am J Vet Res. 1985;46:2104–2109. [PubMed] [Google Scholar]
  • 17.Roizman B, Desrosiers R C, Fleckenstein B, Lopez C, Minson A C, Struddert M J. The family Herpesviridae: an update. Arch Virol. 1992;123:425–449. doi: 10.1007/BF01317276. [DOI] [PubMed] [Google Scholar]
  • 18.Sass B, Mohanty S B, Hetrick F M. Fluorescent antibody study of a new bovine herpesvirus (strain DN-599) Am J Vet Res. 1974;35:1343–1346. [PubMed] [Google Scholar]
  • 19.Soliman A K, Douglas M W, Salib A W, Shehata A E D, Arthur R R, Botros B A M. Application of an immunoperoxidase monolayer assay for the detection of arboviral antibodies. J Virol Methods. 1997;65:147–151. [PubMed] [Google Scholar]
  • 20.Thiry E, Bublot M, Dubuisson J, Pastoret P-P. Bovine herpesvirus-4 infection of cattle. In: Wittmann G, editor. Herpesvirus diseases of cattle, horses and pigs. Developments in veterinary virology. Boston, Mass: Kluwer Academic Publishers; 1989. pp. 95–115. [Google Scholar]
  • 21.Thiry E, Dubuisson J, Bublot M, Van Bressem M-F, Pastoret P-P. The biology of bovine herpesvirus-4 infections in cattle. Dtsch Tierärztl Wochenschr. 1990;97:72–77. [PubMed] [Google Scholar]
  • 22.Thiry E, Bublot M, Dubuisson J, Van Bressem M F, Lequarre A-S, Lomonte P, Vanderplasschen A, Pastoret P-P. Molecular biology of bovine herpesvirus type-4. Vet Microbiol. 1992;33:79–92. doi: 10.1016/0378-1135(92)90037-t. [DOI] [PubMed] [Google Scholar]
  • 23.Truman D, Ludwig H, Storz J. Bovine herpesvirus type 4: studies on the biology and spread in cattle herds and in insemination bulls. J Vet Med B. 1986;33:485–501. [PubMed] [Google Scholar]
  • 24.Van Malderen G, Van Opdenbosch E, Wellemans G. Bovine herpesvirus 1 and 4: a sero-epidemiological survey of the Belgian cattle population. Vlaams Diergeneeskd Tijdschr. 1987;56:364–371. [Google Scholar]
  • 25.Van Opdenbosch E, Wellemans G, Theys H, Verhees I. Occurrence of subclinical viral infections in veal calves and their influence on weight gain. Vlaams Diergeneeskd Tijdschr. 1986;55:17–20. [Google Scholar]
  • 26.Wellemans G, Antoine H, Broes A, Chalier G, Van Opdenbosch E. Isolement d’un virus Herpes chez des bovins atteints de métrite post-partum. Ann Méd Vét. 1983;127:481–482. [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES